Note: This document contains side effect information about copanlisib. Some dosage forms listed on this page may not apply to the brand name Aliqopa.
Applies to copanlisib: intravenous powder for solution.
Serious side effects of Aliqopa
Along with its needed effects, copanlisib (the active ingredient contained in Aliqopa) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking copanlisib:
More common
- Black, tarry stools
- bleeding gums
- blood in the urine or stools
- blurred vision
- chest pain
- chills
- cough
- cracks in the skin
- dizziness
- dry mouth
- fatigue
- flushed, dry skin
- fruit-like breath odor
- headache
- increased hunger
- increased thirst
- increased urination
- loss of heat from the body
- lower back or side pain
- nausea
- nervousness
- painful or difficult urination
- pale skin
- pinpoint red spots on the skin
- pounding in the ears
- red, swollen skin
- scaly skin
- slow or fast heartbeat
- sneezing
- sore throat
- sores, ulcers, or white spots on the lips or in the mouth
- stomach pain
- sweating
- swollen glands
- tightness in the chest
- troubled breathing
- unexplained weight loss
- unusual bleeding or bruising
- unusual tiredness or weakness
- vomiting
Other side effects of Aliqopa
Some side effects of copanlisib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- cracked lips
- diarrhea
- difficulty in swallowing
- lack or loss of strength
- swelling or inflammation of the mouth
For Healthcare Professionals
Applies to copanlisib: intravenous powder for injection.
General
The most common (20% or greater) adverse reactions were hyperglycemia, decreased hemoglobin, decreased lymphocyte count, decreased white blood cell count, decreased platelet count, decreased neutrophil count, hypertriglyceridemia, hypophosphatemia, diarrhea, decreased general strength and energy, hypertension, leukopenia, neutropenia, nausea, hyperuricemia, thrombocytopenia, lower respiratory tract infections, and increased serum lipase.[Ref]
Endocrine
Very common (10% or more): Hyperglycemia (95%)[Ref]
Hematologic
Very common (10% or more): Decreased hemoglobin (78%), decreased lymphocyte count (78%), decreased white blood cell count (71%), decreased platelet count (65%), decreased neutrophil count (63%), leukopenia (36%), neutropenia/febrile neutropenia (32%), thrombocytopenia (22%)[Ref]
Metabolic
Very common (10% or more): Hypertriglyceridemia (58%), hypophosphatemia (44%), increased serum lipase (21%)[Ref]
Gastrointestinal
Very common (10% or more): Diarrhea (36%), nausea (26%), stomatitis/oral pain/oropharyngeal erosion and ulcer (14%), vomiting (13%)[Ref]
Other
Very common (10% or more): Decreased general strength and energy/fatigue/asthenia (36%)
Common (1% to 10%): Mucosal inflammation[Ref]
Genitourinary
Very common (10% or more): Hyperuricemia (25%)[Ref]
Respiratory
Very common (10% or more): Lower respiratory tract infections (21%)
Common (1% to 10%): Pneumonitis[Ref]
Nervous system
Common (1% to 10%): Paresthesia, dysesthesia[Ref]
Dermatologic
Very common (10% or more): Rash/exfoliative skin reactions (15%)[Ref]
Cardiovascular
Very common (10% or more): Hypertension/secondary hypertension (13%)[Ref]
